Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched studyResearch in context

Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched studyResearch in context

Summary: Background: Abemaciclib is currently approved for the adjuvant treatment of high-risk, lymph node (LN)-positive, hormone receptor (HR)-positive breast cancer (BC). In a real-world setting the clinicopathologic features of patients potentially eligible for adjuvant abemaciclib remain to be...

Full description

Bibliographic Details
Main Authors: Francesca Magnoni, Giovanni Corso, Patrick Maisonneuve, Beatrice Bianchi, Giuseppe Accardo, Claudia Sangalli, Giulia Massari, Anna Rotili, Luca Nicosia, Filippo Pesapane, Emilia Montagna, Giovanni Mazzarol, Viviana Galimberti, Paolo Veronesi, Giuseppe Curigliano
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:EClinicalMedicine
Subjects:
Invasive lobular breast cancer
Invasive ductal breast cancer
Abemaciclib
MonarchE trial
Recurrence
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537024001317

Internet

http://www.sciencedirect.com/science/article/pii/S2589537024001317

Similar Items